Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine... (ed onneurological and psychiatric disord...)

Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura

Date:10/24/2008

ed on neurological and psychiatric disorders. Its principal pipeline assets are tonabersat, under development in the preventive treatment of migraine, and sabcomeline in schizophrenia. Worldwide rights to both compounds were acquired from GlaxoSmithKline and the compounds benefit from comprehensive safety tolerance data as a result of investment by GSK.

Tonabersat is the leading compound in an exciting new class of selective drugs designated as neuronal gap junction blockers and offers the potential to prevent the onset of migraine as a preferred alternative to acute treatment. Sabcomeline, a muscarinic partial agonist, has potential in the treatment of chronic schizophrenia.

Minster's near-term focus is on the development and commercialization of its current pipeline. Its medium term strategy is to leverage the anticipated cashflows from the current pipeline by in-licensing further compounds with the ultimate objective of creating a substantial and highly efficient drug development enterprise focused on the central nervous system.

Minster joined the AIM market in February 2005 and trades under the symbol MPM. For further information please visit http://www.minsterpharma.com .

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
2. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
3. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
4. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
5. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
6. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
7. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
8. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
9. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
10. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
11. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society

Post Your Comments:

Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine...(ed onneurological and psychiatric disord...),Health